Creating value for our shareholders

Verona Pharma (Nasdaq: VRNA) is focused on developing and commercializing innovative life-enhancing treatments for chronic respiratory diseases. Our first-in-class investigational drug, ensifentrine, is under review by the US FDA for the maintenance treatment of COPD. The Company is led by an experienced management team with an established track record in the discovery, clinical development and commercialization of respiratory therapeutics.


16.99 USD

Investor Presentation

View our latest presentation


Explore our recent results

Latest News

PDUFA Target Action Date for Ensifentrine of June 26, 2024  Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /…

Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma…

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and…

LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call

LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as…

Latest Events




Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update




42nd Annual J.P. Morgan Healthcare Conference

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.